Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score
Articolo
Data di Pubblicazione:
2022
Abstract:
Immunotherapy with atezolizumab plus bevacizumab represents the new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC). Prognostic biomarkers are an unmet need.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
C-reactive protein; alpha-fetoprotein; immune checkpoint inhibitor; liver cancer
Elenco autori:
Scheiner, Bernhard; Pomej, Katharina; Kirstein, Martha M; Hucke, Florian; Finkelmeier, Fabian; Waidmann, Oliver; Himmelsbach, Vera; Schulze, Kornelius; von Felden, Johann; Fründt, Thorben W; Stadler, Marc; Heinzl, Harald; Shmanko, Kateryna; Spahn, Stephan; Radu, Pompilia; Siebenhüner, Alexander R; Mertens, Joachim C; Rahbari, Nuh N; Kütting, Fabian; Waldschmidt, Dirk-Thomas; Ebert, Matthias P; Teufel, Andreas; De Dosso, Sara; Pinato, David J; Pressiani, Tiziana; Meischl, Tobias; Balcar, Lorenz; Müller, Christian; Mandorfer, Mattias; Reiberger, Thomas; Trauner, Michael; Personeni, Nicola; Rimassa, Lorenza; Bitzer, Michael; Trojan, Jörg; Weinmann, Arndt; Wege, Henning; Dufour, Jean-François; Peck-Radosavljevic, Markus; Vogel, Arndt; Pinter, Matthias
Link alla scheda completa:
Link al Full Text:
Pubblicato in: